Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Moving Towards a Universal Flu Vaccine

Published: Monday, December 31, 2012
Last Updated: Monday, December 31, 2012
Bookmark and Share
Israeli company reports good results with supplemental shot in elderly.

Multimeric-001, an influenza vaccine now in clinical trials, boosts immunity in elderly people when given as a supplement to the seasonal shot.

But supplementation is just a short-term goal: eventually the drug’s maker, BiondVax Pharmaceuticals of Ness Ziona, Israel, believes that Multimeric-001 alone could protect against all strains of flu.

The company will present the results from its second phase II trial of the shot on 3 April at the Second Annual Vaccines Congress in London.

The 90 people aged 65 and older who got the pair of shots, compared to 30 who received only the annual vaccine, mounted a stronger immune response to the three seasonal flu strains, as well as to a few other strains not in the seasonal vaccine.

For most infectious agents, one exposure teaches the body’s immune system to recognize and destroy the virus or bacterium. The standard flu vaccine teaches the body to recognize the virus's outer coating.

But influenza is constantly changing its stripes, mutating from year to year and forcing scientists to guess which three strains to include in the seasonal vaccine.

“This is crazy,” says Vincent Racaniello, a virologist at Columbia University in New York, who is not involved with the Biondvax trials. If there were one vaccine that worked for any kind of flu, no matter how it mutated its coat, the costs of protection would drop and pandemics could disappear, he says.

The Multimeric-001 vaccine comprises nine linked sections from three flu proteins from different parts of the virus. These represent a “common denominator” shared by more than 10,000 flu strains since 1940, says the company’s chief scientist Tamar Ben-Yedidia. Racaniello says that, in theory, this combination or proteins should be universal, because every strain of flu would have them.

In a study published in February in the Journal of Clinical Immunology1, BiondVax reported that its Multimeric-001 vaccine was safe and conferred immunity on its own. However, BiondVax thinks that a universal flu vaccine would be a tough sell to regulatory agencies.

Part of the challenge is that the standard test for a vaccine’s efficacy is based on the presence of antibodies to the ever-changing parts of the haemagglutinin protein on the outside of the virus in a vaccinated person's blood. It’s a test their universal vaccine is designed to fail, because Multimeric-001 does not confer immunity to these proteins.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!